ARS Pharmaceuticals shares rise 15.34% intraday after China approves neffy 2 mg epinephrine nasal spray.

ARS Pharmaceuticals surged 15.34% intraday after China’s National Medical Products Administration approved neffy 2 mg epinephrine nasal spray for emergency treatment of allergic reactions in adults and children weighing at least 30 kg. The approval, branded as 优敏速®, expands the company’s access to a Chinese market with tens of millions at risk of severe food allergies. This regulatory milestone, combined with a pending pediatric 1 mg filing, strengthens ARS Pharmaceuticals’ global expansion narrative, particularly following Japan’s 2025 approval of both 1 mg and 2 mg neffy doses. The move reflects investor optimism about scaling neffy’s market reach in high-potential regions, despite broader volatility (30-day return of 11% but a year-to-date decline of 3.39%). The approval aligns with the stock’s intraday rally, underscoring the significance of regulatory progress in driving short-term sentiment.